Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus

Rheumatology International

Volumn 31, Issue 9, 2011, Pages 1215-1218

  Ngamjanyaporn, Pintip ^a   Thakkinstian, Ammarin ^a   Verasertniyom, Oravan ^a   Chatchaipun, Porntip ^a   Vanichapuntu, Monchand ^a   Nantiruj, Kanokrat ^a   Totemchokchyakarn, Kitti ^a   Attia, John ^b   Janwityanujit, Suchela ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Cyclophosphamide; CYP2C19; Ovarian toxicity; Pharmacogenetics; SLE (systemic lupus erythematosus)

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C19;

ADULT; AMENORRHEA; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUATION; OVARY DISEASE; OVARY TOXICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THAILAND;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; FEMALE; GENE FREQUENCY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OVARIAN DISEASES; POLYMORPHISM, GENETIC; THAILAND; YOUNG ADULT;

EID: 80054945119     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1420-7     Document Type: Article

References (13)

1. Johnson AE, Gordon C, Palmer RG, Bacon PA (1995) The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 38(4):551-558
2. Mok CC, Lau CS (2003) Lupus in Hong Kong Chinese. Lupus 12(9):717-722 (Pubitemid 37173672)
3. Langevitz P, Klein L, Pras M, Many A (1992) The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 28(3-4):157-158 (Pubitemid 23044819)
4. Wang CL, Wang F, Bosco JJ (1995) Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 4(1):11-14
5. McDermott EM, Powell RJ (1996) Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclo-phosphamide. Ann Rheum Dis 55(4):224-229 (Pubitemid 26122247)
6. Souhami R, Tannock I, Hohenberger P, Horiot J-C (2001) Oxford Textbook of Oncology, 2nd edn. Oxford University press, New York
7. Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, Hassan M, Dahl ML (2003) Bioactivation of cyclo-phosphamide: the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 59(2):103-109 (Pubitemid 36793721)
8. Timm R, Kaiser R, Lotsch J, Heider U, Sezer O, Weisz K, Montemurro M, Roots I, Cascorbi I (2005) Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J 5(6):365-373
9. Lamba JK, Dhiman RK, Kohli KK (2000) CYP2C19 genetic mutations in north Indians. Clin Pharmacol Ther 68(3):328-335
10. Tassaneeyakul W, Tawalee A, Tassaneeyakul W, Kukongviriyapan V, Blaisdell J, Goldstein JA, Gaysornsiri D (2002) Analysis of the CYP2C19 polymorphism in a northeastern Thai population. Pharmacogenetics 12(3):221-225 (Pubitemid 34596786)
11. Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, Na-Bangchang K, Tawalee A, Krikreangsak N, Cykleng U, Tass-aneeyakul W (2006) CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet 21(4):286-290
12. Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG (2004) Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 50(7):2202-2210 (Pubitemid 38924398)
13. Singh G, Saxena N, Aggarwal A, Misra R (2007) Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 34(4):731-733 (Pubitemid 46641378)